We have scalable, validated biologic drug candidates that are effective against therapy resistant cancers in preclinical models and are seeking partners interested in joining our effort to advance to first in human trials. We have been honored to receive awards in multiple business competitions, such as LES International Business Plan Contest and Wisconsin Governor’s Business Plan Contest. As “SE Wisconsin Innovator of the Year”, we have received seed funding from Bridge to Cures and the Wisconsin Economic Development Council, and are pursuing additional non-dilutive seed funding. Essential Biotechnology is further seeking investment for lead prioritization and optimization and progression of therapeutics including monoclonal antibody ESS102 through Phase I/II clinical trials. We anticipate completion of Phase I trials and proof of concept in humans, with licensing/acquisition as early as 2019. Potential investors: Please contact us for information:

Essential Biotechnology logo

Essential Biotechnology Wins SE Wisconsin Healthcare Innovation Pitch Event! < Click for story.